Skip to Content

Orencia Dosage

Generic name: abatacept 250mg in 15mL
Dosage form: injection, powder, lyophilized, for solution

Medically reviewed by Drugs.com. Last updated on Jun 17, 2020.

Dosage in Adult Rheumatoid Arthritis

For adult patients with RA, administer as an intravenous infusion or as a subcutaneous injection. ORENCIA may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than JAK inhibitors or bDMARDs (e.g., TNF antagonists).

Intravenous Dosing Regimen

Reconstitute ORENCIA lyophilized powder and administer after dilution [see Dosage and Administration (2.4)] as a 30-minute intravenous infusion utilizing the weight range-based dosing specified in Table 1. Following the initial intravenous infusion, administer as an intravenous infusion at 2 and 4 weeks and every 4 weeks thereafter.

Table 1: Dose of ORENCIA for Intravenous Infusion in Adult RA Patients
Body Weight of Adult Patient Dose Number of Vialsa
a Each vial provides 250 mg of abatacept for administration.

Less than 60 kg

500 mg

2

60 to 100 kg

750 mg

3

More than 100 kg

1000 mg

4

Subcutaneous Dosing Regimen

Prior to the first subcutaneous dose, may administer an optional loading dose as a single intravenous infusion (as per body weight categories in Table 1). If an intravenous loading dose is used, administer the first subcutaneous injection within one day of the infusion. Administer ORENCIA 125 mg in prefilled syringes or in ORENCIA ClickJect™ autoinjector by subcutaneous injection once weekly [see Dosage and Administration (2.5)].

For patients switching from ORENCIA intravenous therapy to subcutaneous administration, administer the first subcutaneous dose instead of the next scheduled intravenous dose.

Dosage in Polyarticular Juvenile Idiopathic Arthritis

For patients with polyarticular juvenile idiopathic arthritis (pJIA), may administer ORENCIA as an intravenous infusion (only patients 6 years of age and older) or a subcutaneous injection (only patients 2 years of age and older) [see Use in Specific Populations (8.4)]. ORENCIA may be used as monotherapy or concomitantly with methotrexate.

Intravenous Dosing Regimen

Administer ORENCIA as a 30-minute intravenous infusion based on body weight [see Dosage and Administration (2.4)]:

If less than 75 kg, administer a dose of 10 mg/kg.
If 75 kg or greater, administer as per the recommendations in Table 1 (follow the adult intravenous dosing regimen), not to exceed a maximum dose of 1000 mg.

Following the initial intravenous infusion, administer infusions at 2 and 4 weeks and every 4 weeks thereafter. Immediately discard any unused portion in the vials.

Subcutaneous Dosing Regimen

Administer ORENCIA for subcutaneous injection, without an intravenous loading dose, utilizing the weight range-based dosing as specified in Table 2 [see Dosage and Administration (2.5)]. Subsequently administer once weekly.

Table 2: Dose of ORENCIA for Subcutaneous Administration in Patients 2 Years of Age or Older with JIA
Body Weight of Pediatric Patient Dose (once weekly)

10 to less than 25 kg

50 mg

25 to less than 50 kg

87.5 mg

50 kg or more

125 mg

PJIA patients may self-inject with ORENCIA or the patient’s caregiver may administer ORENCIA if both the healthcare practitioner and the parent/legal guardian determines it is appropriate. The ability of pediatric patients to self-inject with the autoinjector has not been tested.

Dosage in Adult Psoriatic Arthritis

For adult patients with psoriatic arthritis, administer as an intravenous infusion or a subcutaneous injection.

ORENCIA may be used with or without non-biologic DMARDs.

Intravenous Dosing Regimen

Administer ORENCIA as a 30-minute intravenous infusion utilizing the weight range-based dosing specified in Table 1. Following the initial intravenous administration, administer an intravenous infusion at 2 and 4 weeks and every 4 weeks thereafter.

Subcutaneous Dosing Regimen

Administer 125 mg of ORENCIA subcutaneously once weekly (no intravenous loading dose is needed) [see Dosage and Administration (2.5)].

For patients switching from ORENCIA intravenous infusions to subcutaneous administration, administer the first subcutaneous dose instead of the next scheduled intravenous dose.

Preparation and Administration Instructions for Intravenous Infusion

Calculate the ORENCIAdose, the total volume of reconstituted solution required, and the number of ORENCIA vials needed. For a full dose, less than the full contents of one vial or more than one vial may be needed. Using aseptic technique, reconstitute, dilute, and then administer ORENCIA as follows:

Reconstitution

1)
Use the vial only if the vacuum is present.
2)
Reconstitute each vial of supplied ORENCIA lyophilized powder (each vial supplies 250 mg of abatacept) with 10 mL of Sterile Water for Injection, USP (direct the stream toward the inside wall of the vial) to obtain a concentration of 25 mg/mL. Use only the provided silicone-free syringe with an 18- to 21-gauge needle:
a.
If the ORENCIA lyophilized powder is accidently reconstituted using a siliconized syringe, the solution may develop a few translucent particles (discard any solutions prepared using siliconized syringes).
b.
If the silicone-free disposable syringe is dropped or becomes contaminated, use a new silicone-free disposable syringe. To obtain new silicone-free syringes, contact Bristol-Myers Squibb at 1-800-ORENCIA.
3)
Gently swirl the vial to minimize foam formation, until the contents are completely dissolved. Do not shake. Avoid prolonged or vigorous agitation.
4)
Upon complete dissolution of the lyophilized powder, vent the vial with a needle to dissipate any foam that may be present.
5)
Visually inspect the reconstituted solution (the solution should be clear and colorless to pale yellow). Do not use if opaque particles, discoloration, or other foreign particles are present.
6)
Repeat steps 2) through 5) if two, three, or four vials are needed for a dose (see Table 1).

Dilution

7)
Must further dilute the reconstituted ORENCIA solution to 100 mL as follows:
a.
From a 100 mL infusion bag or bottle of 0.9% Sodium Chloride Injection, USP, withdraw a volume equal to the volume of the reconstituted ORENCIA solution required for the patient’s dose.
b.
Slowly add the reconstituted ORENCIA solution(s) into the infusion bag or bottle using the silicone-free disposable syringe provided with each vial.
c.
Gently mix. Do not shake the bag or bottle. The final concentration of abatacept in the bag or bottle will depend upon the amount of abatacept added, but will be no more than 10 mg/mL. Immediately discard any unused portion in the ORENCIA vial.

Administration

8)
Prior to administration, visually inspect the ORENCIA diluted solution for particulate matter and discoloration. Discard the diluted solution if any particulate matter or discoloration is observed.
9)
Administer the entire diluted ORENCIA solution over a period of 30 minutes with an infusion set and a sterile, non-pyrogenic, low-protein-binding filter (pore size of 0.2 μm to 1.2 μm).
10)
Must complete the infusion of the diluted ORENCIA solution within 24 hours of reconstitution of the ORENCIA vials.

Do not infuse ORENCIA concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of ORENCIA with other drugs.

Storage of Diluted ORENCIA Solution

May store the diluted ORENCIA solution at room temperature or refrigerate at 2ºC to 8ºC (36ºF to 46ºF) up to 24 hours before use. Discard the diluted solution if not administered within 24 hours.

Recommendations for Subcutaneous Administration

ORENCIA prefilled syringes and ORENCIA ClickJect autoinjectors are intended for:

subcutaneous use only and are not intended for intravenous infusion
use under the guidance of a healthcare practitioner.

After proper training in subcutaneous injection technique, a patient or the patient’s caregiver may administer a subcutaneous injection of ORENCIA (ClickJect autoinjector or prefilled syringe) if a healthcare practitioner determines that it is appropriate. Instruct patients and/or caregivers to follow the directions provided in the Instructions for Use for additional details on administration. Specifically instruct them to inject the full amount (which provides the proper dose of ORENCIA), rotate injection sites, and to avoid injections into areas where the skin is tender, bruised, red, or hard.

Visually inspect for particulate matter and discoloration prior to administration. Do not use ORENCIA prefilled syringes or ORENCIA ClickJect autoinjectors exhibiting particulate matter or discoloration. ORENCIA should be clear to slightly opalescent and colorless to pale yellow.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions